Our news

Crossject USA: new appointment

Crossject appoints Don Zinn as VP US Business

Read more

ZENEO® Adrenaline: a new innovative formulation

Crossject has developed a new innovative formulation for ZENEO® Adrenaline to strengthen its commercial potential.

Cooperative agreement signed between Crossject and the US Department of Defense

Crossject and the US Department of Defense have signed a cooperative research and development agreement for Zeneo® Midazolam

ZENEO® Midazolam earns the orphan drug designation

The FDA has granted Orphan Drug designation to ZENEO® Midazolam for the treatment of status epileptics.